The New England journal of medicine, 2021-07, Vol.385 (5), p.395-405
- Gnant, Michael
- Fitzal, Florian
- Rinnerthaler, Gabriel
- Steger, Guenther G
- Greil-Ressler, Sigrun
- Balic, Marija
- Heck, Dietmar
- Jakesz, Raimund
- Thaler, Josef
- Egle, Daniel
- Manfreda, Diether
- Bjelic-Radisic, Vesna
- Wieder, Ursula
- Singer, Christian F
- Melbinger-Zeinitzer, Elisabeth
- Haslbauer, Ferdinand
- Sevelda, Paul
- Trapl, Harald
- Wette, Viktor
- Wimmer, Kerstin
- Gampenrieder, Simon P
- Bartsch, Rupert
- Kacerovsky-Strobl, Stephanie
- Suppan, Christoph
- Brunner, Christine
- Deutschmann, Christine
- Soelkner, Lidija
- Fesl, Christian
- Greil, Richard
2021
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Gnant, Michael
- Fitzal, Florian
- Rinnerthaler, Gabriel
- Steger, Guenther G
- Greil-Ressler, Sigrun
- Balic, Marija
- Heck, Dietmar
- Jakesz, Raimund
- Thaler, Josef
- Egle, Daniel
- Manfreda, Diether
- Bjelic-Radisic, Vesna
- Wieder, Ursula
- Singer, Christian F
- Melbinger-Zeinitzer, Elisabeth
- Haslbauer, Ferdinand
- Sevelda, Paul
- Trapl, Harald
- Wette, Viktor
- Wimmer, Kerstin
- Gampenrieder, Simon P
- Bartsch, Rupert
- Kacerovsky-Strobl, Stephanie
- Suppan, Christoph
- Brunner, Christine
- Deutschmann, Christine
- Soelkner, Lidija
- Fesl, Christian
- Greil, Richard
- Titel
- Duration of Adjuvant Aromatase-Inhibitor Therapy in Postmenopausal Breast Cancer
- Ist Teil von
- The New England journal of medicine, 2021-07, Vol.385 (5), p.395-405
- Ort / Verlag
- United States: Massachusetts Medical Society
- Erscheinungsjahr
- 2021
- Quelle
- MEDLINE
- Beschreibungen/Notizen
- Postmenopausal women with hormone-receptor–positive breast cancer who had received 5 years of adjuvant endocrine therapy were randomly assigned to an additional 2 years or 5 years of therapy with the aromatase inhibitor anastrozole. No between-group differences were noted in disease-free survival, but patients in the 5-year group had more bone fractures.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0028-4793eISSN: 1533-4406DOI: 10.1056/NEJMoa2104162Titel-ID: cdi_proquest_miscellaneous_2556387231
- Format
- –
- Schlagworte
- Adjuvants, Administration, Oral, Aged, Anastrozole, Anastrozole - administration & dosage, Anastrozole - adverse effects, Antineoplastic Agents, Hormonal - administration & dosage, Antineoplastic Agents, Hormonal - therapeutic use, Aromatase, Aromatase Inhibitors - administration & dosage, Aromatase Inhibitors - adverse effects, Bone cancer, Breast Cancer, Breast Neoplasms - drug therapy, Breast Neoplasms - mortality, Breast Neoplasms - surgery, Cancer therapies, Chemotherapy, Adjuvant, Colorectal carcinoma, Disease-Free Survival, Endocrine therapy, Fractures, Fractures, Bone - epidemiology, Fractures, Bone - etiology, Hematology, Humans, Kaplan-Meier Estimate, Mammography, Middle Aged, Neoplasm Recurrence, Local - prevention & control, Oncology, Osteoporosis, Patients, Post-menopause, Postmenopause, Prospective Studies, Receptors, Estrogen, Receptors, Progesterone, Survival, Tamoxifen - therapeutic use, Treatments in Oncology, Ultrasonic imaging, Womens health